An Extension of the TG1101-RMS201 Trial
NCT03381170
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
48
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
BIOLOGICAL:
Ublituximab
Sponsor
TG Therapeutics, Inc.